This document contains information to assist applicants submitting either a Stage 1 or Stage 2 application form. Applications for funding are made online through the NIHR Research Awards Lifecycle Management System (REALMS). You must register or log-in to the REALMS to complete and submit your application.
Please also ensure that you have read the Stage 1 application form guidance or the Stage 2 application form guidance notes fully and referred to the NIHR HTA programme website before contacting us with any queries. We have endeavoured to cover all necessary information relating to the application form through these resources. Incorrectly completed applications may be rejected.
The following additional supporting information is available on the NIHR Website:
- HTA Programme page / aims and scope
- How to apply for funding
- HTA Tips for Applicants
- Word version of Stage 1 application form
- Word version of Stage 2 application form
Other information / links
The HTA Programme – purpose and eligibility
The NIHR Health Technology Assessment programme is funded by the NIHR, with contributions from the CSO in Scotland, Health and Care Research in Wales and the HSC R&D Division, Public Health Agency in Northern Ireland. Researchers from Northern Ireland and Scotland for certain NICE related calls, as indicated in the commissioning brief, should contact the HTA Commissioning Team firstname.lastname@example.org to discuss their eligibility to apply.
If you intend to apply to the researcher led work-stream should read the remit sections of the HTA webpage and then identify the right programme page of the NIHR website to check whether your proposed research is in the remit of the HTA programme. You may also find it useful to refer to the portfolio of funded projects to see what similar projects we have funded in the past.
If after reviewing this guidance you have any questions about the eligibility of your proposed research for HTA funding please send an email to email@example.com giving a brief summary of the research proposed, including the population, intervention, comparator, outcome and setting as appropriate. Applicants are asked to:
- Follow Good Clinical Practice guidelines when planning how studies, particularly RCTs, will be supervised. Further advice specific to each topic will be given by the HTA Programme at proposal Stage 2 and contracting stages.
- Note that trials involving medicinal products must comply with "The Medicines for Human Use (Clinical Trials) Regulations 2004". In the case of such trials, the DHSC expects the employing institution of the chief investigator to be nominated as the sponsor. Other institutions may wish to take on this responsibility or agree co-sponsorship with the employing institution. The DHSC is prepared to accept the nomination of multiple sponsors. Applicants who are asked to submit a Stage 2 proposal will need to obtain confirmation of a sponsor(s) to complete their application. The DHSC reserve the right to withdraw from funding the project if they are not satisfied with the arrangements put in place to conduct the trial.
Other programmes' proposal resubmission policy
Please note that an unsuccessful proposal cannot normally be resubmitted to this or the Efficacy and Mechanism Evaluation (EME), Health and Social Care Delivery Research (HSDR) or Public Health Research (PHR) programmes within one year of the original decision letter, unless applicants can demonstrate that it has changed significantly and is essentially a new proposal.
NIHR will not accept the same or substantially similar applications to more than one NIHR programme. If two similar applications are submitted, once the overlap is identified, the application that is most advanced through the funding process will continue and the second will not be taken further.
Similar applications will only be considered by two programmes concurrently if:
- the aims and research proposals are substantially different
- if successful, NIHR would be prepared to fund both proposals
- the successful delivery of one project is not dependent on the other
We have an obligation to keep data secure and to use it appropriately. To fulfil our obligations under law and as a result of our contract with the Department of Health and Social Care, we adopt various procedures to use and protect data. This will impact on how we deal with you and your joint applicants.
The Department of Health and Social Care (DHSC) NIHR is the Data Controller under the Data Protection Act 1998 ('the Act'). Under the Data Protection Act, we have a legal duty to protect any information we collect from you. You should be aware that information given to us might be shared with other DHSC NIHR bodies for the purposes of statistical analysis and other DHSC NIHR research management purposes. NIHR also reserves the right to share, in confidence, details of your application with other approved research funding organisations outside NIHR in order to coordinate research activity in the UK.
Information collected from you will not be passed to any third party outside the NIHR except specifically as detailed above without your consent except where we are under a statutory obligation or entitled to do so by law. Applicants may be assured that DHSC NIHR is committed to protecting privacy and to processing all personal information in a manner that meets the requirements of the Act.
Data security - data about you
Personal information will be held on a database in the NIHR password-protected network that is available only to NIHR staff. Your details and those of your co-applicants will be retained by the NIHR on behalf of the DHSC to facilitate the running of the HTA Programme. If your application is successful at any stage of our process, your name, and the details of the sponsoring organisation, will appear on the NIHR website. In addition, once funding has been agreed and the contract signed, your details will appear in other literature as a grant holder and will be passed to the DHSC for inclusion in their publicly available databases of research projects.
Your name and those of your co-applicants will be added to our mailing list. This means that you will be sent updates on all the NIHR programmes. We may also send you separate literature about the HTA Programme and related events in medical/health research. If you have any questions, or if you would prefer not to receive routine and/or general communications, please contact us at: firstname.lastname@example.org.
Research Design Service
Applicants are recommended to seek advice from suitable methodological support services, at an appropriate stage in the development of their research idea and application. It is advisable to make contact at an early a stage as possible to allow sufficient time for discussion and a considered response.
The NIHR Research Design Service can advise on appropriate NIHR programme choice, and developing and designing high quality research grant applications.
Clinical Trials Unit support
Clinical Trials Units are regarded as an important component of many trial applications, and can advise and participate throughout the process from initial idea development through to project delivery and reporting. However, they may not be essential for all types of studies. If you feel this is the case, please justify the reasons on your application.
If you are looking for a CTU to collaborate with in your application, then the following sources can provide more help:
NIHR CTU Support Funding provides information on units receiving funding form the NIHR to collaborate on research applications to NIHR programmes and funded projects.
The UKCRC CTU Network provides a searchable information resource on all registered units in the UK, and lists key interest areas and contact information.
Clinical Trials Toolkit
Researchers designing or undertaking clinical trials are encouraged to consult the Clinical Trials Toolkit. This NIHR resource is a website designed to help researchers navigate through the complex landscape of setting up and managing clinical trials in line with regulatory requirements. Although primarily aimed at those involved in publicly funded Clinical Trials of Investigational Medicinal Products (CTIMPs), the Toolkit will also benefit researchers and R&D staff working on trials in other areas, who will find useful information and guidance of relevance to the wider trials environment.
Wherever possible, the results of HTA should provide information about the effectiveness and cost effectiveness of care provided in its usual clinical setting and for the diverse subjects who would be eligible for the interventions under study. The endpoints of interest will in most cases include disease specific measures, health related quality of life and costs (directly and indirectly related to patient management). Wherever possible, these measurements should be made by individuals who are unaware of the treatment allocation of the subjects they are assessing. We encourage applicants to involve users of health care in the preparation of their proposal, for instance in selecting patient oriented outcomes. Where established Core Outcomes exist they should be included amongst the list of outcomes unless there is good reason to do otherwise. Please see The COMET Initiative website to identify whether Core Outcomes have been established. A period of follow up should be undertaken which is sufficient to ensure that a wider range of effects are identified other than those which are evident immediately after treatment. Where relevant, researchers should explore the effect of the intervention in relation to health inequalities. These factors should guide applicants in their choice of subjects, settings and measurements made.
INVOLVE / public involvement
The NIHR expects the active involvement of patients and the public in the research it supports, including research undertaken as part of an individual training award. NIHR recognise that the nature and extent of active patient and public involvement is likely to vary depending on the context of each study or award. The term involvement refers to an active partnership between patients, members of the public and researchers in the research process. This can include, for example, involvement in the choice of research topics, assisting in the design, advising on the research project or in carrying out the research.
It is important that you describe in as much detail as possible how patients and the public have been involved in the development of the application as well as plans for involvement in the proposed research. Please note that this does not refer to the recruitment of patients or members of the public as participants in the research.
Further information and resources can be found on the Make a Strong Application page. This includes a detailed definition of patient and public involvement in research, briefing notes for researchers on how to involve patients and the public and payment guidance. The NIHR Research Design Service provide advice on developing research applications including involving patients and the public and the James Lind Alliance has a step-by-step guide on involvement in research identification and priority setting.
Ethics / regulatory approvals
Guidance on the application process for ethical and other approvals can be found on the HRA website. Please note that if your study is led from England and involves the NHS in England you should apply for HRA approval .
If you are using patient information from an existing database, you should check whether the patients have given their consent for their data to be included in that database for research purposes, or if not whether the database is exempt under Section 251 of the NHS Act 2006. Where exemptions are not already in place, approval to use confidential patient information without consent must be requested from the HRA who make decisions with advice from the Confidentiality Advisory Group (CAG).
To take advantage of the growing utility of routine data (such as HES, GP records etc.), we would encourage investigators, where appropriate, to ask study participants to consent to long term follow up (e.g. beyond the outcomes to be collected in the funded trial) using routinely collected data, and appropriate linkage to allow this data to be best used.
Information on the responsibilities of key research stakeholders including Sponsors, Chief Investigators and Research Teams are summarised in the UK policy framework for health and social care research .
Reasonable costs and value for money
The HTA programme accepts that some variance in costs is likely to occur between the Stage 1 and Stage 2 applications. The HTA programme will carefully scrutinise all Stage 2 application costs and any variance from the first stage. All costs need to be fully justified by the applicants to reassure that the study offers good value for money for the NHS.
It is important that consideration is given to all costs in relation to NHS support and treatment costs and the accurate values for these are included. It should be noted that applicants are expected to have contacted the appropriate Trust/s regarding the NHS support and treatment costs that may be required if their research is funded. If the costs are felt to be material, a letter of support may be provided from the Trust/s concerned as part of the Stage 2 proposal.
There are no fixed limits on the duration of projects or funding, and proposals should be tailored to fully address the research problem. Research costs are the costs of the research activity itself. These include data collection, analysis, other activities needed to answer the research questions, trial registration (if required) and the salary and indirect costs of staff employed to carry out the research.
If you are unsure of how to attribute the costs between research and NHS support and treatment costs, please refer to the following guidance on ‘Attributing the costs of health & social care Research & Development (AcoRD)’.
Higher Education Institutions (HEIs) should determine the Full Economic Cost (FEC) of their research using the Transparent Approach to Costing (TRAC) methodology. For HEIs, up to 80% of FEC will be paid, provided that TRAC methodology has been used.
For applications where the contractor is an NHS body or provider of NHS services in England, up to 100% of direct costs will be paid.
The total costs on the Stage 1 form should include the figures at the appropriate rate, so the total should reflect HEI figures at 80% and non-HEI figures at 100%. When completing the Stage 2 form, the figure submitted should be 100%, any reductions to FEC are automatically calculated by the system prior to submission.
Feasibility and pilot studies
We expect that when external pilot or feasibility studies are specified in commissioning briefs, a clear route to the substantive study will be described but unless specified in the brief the substantive trial should not be included as part of the study design. A decision on the substantive study will be made at an appropriate time-point during the pilot/feasibility work. The HTA reserve the right to directly commission research or advertise for the substantive study.
Where requested, any internal or embedded pilot study should have clear and robust progression criteria.
Feasibility Studies are pieces of research done before a main study. They are used to estimate important parameters that are needed to design the main study. Feasibility studies for randomised controlled trials may not themselves be randomised. Crucially, feasibility studies do not evaluate the outcome of interest; that is left to the main study. If a feasibility study is a small randomised controlled trial, it need not have a primary outcome and the usual sort of power calculation is not normally undertaken. Instead the sample size should be adequate to estimate the critical parameters (e.g. recruitment rate) to the necessary degree of precision.
Pilot Studies are a version of the main study that is run in miniature to test whether the components of the main study can all work together. It is focused on the processes of the main study, for example to ensure recruitment, randomisation, treatment, and follow-up assessments all run smoothly. It will therefore resemble the main study in many respects. In some cases this will be the first phase of the substantive study and data from the pilot phase may contribute to the final analysis; this can be referred to as an internal pilot. Or at the end of the pilot study the data may be analysed and set aside, a so-called external pilot.
For a full definition of the terms 'feasibility study' and 'pilot study' visit the NIHR website glossary page.
In preparing for a substantive evaluation attention should be paid to appropriate guidance on how to develop interventions (such as the MRC guidance on developing and evaluating complex interventions and the IDEAL framework.
Diagnostics and imaging
In evaluating diagnostic and imaging techniques, the emphasis of the HTA Programme is to assess the effect on patient management and outcomes (particularly where changes in management can be shown to have patient benefits). Improvements in diagnostic accuracy, whilst relevant, are not the primary interest of this commissioned research programme. Applicants should justify where they consider improvements in diagnostic accuracy to be relevant to these objectives. Where there is poor evidence to link diagnostic improvements to patient benefits, part of the primary research may be to assess the effects of such changes on patient outcome.
An assessment should also be made of changes in other resources (particularly other subsequent therapies) used as a result of changes in diagnostic methods.
UK Biobank is a major national health resource with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses. As such, applicants are encouraged to consider whether Biobank may be able to provide suitable data for their study, rather than request funding for unnecessary new data collection. We do not want to discourage establishment of new cohorts of participants and their data where this is necessary to address the research questions under consideration, our aim is to avoid applications for funding to set up Biobank-like cohorts where the use of Biobank would prevent wasteful duplication of Biobank-like activities.
UK Biobank has recruited 500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis as well as detailed information about themselves. The health of members of this large cohort will be followed over the coming years and the participants have consented to be approached about health research.
Please note: Some of the NIHR programmes, including the HTA Programme, are unlikely to fund work which focuses on collection of physiological, biochemical or other information unless there is a clearly defined way in which this will be used for the benefit of patients (either directly or in terms of improving outcomes of other patients). For these reasons we generally do not fund bio-banks or disease registers. If you would like to include this as an element of your research proposal, please contact us.
Systematic reviews and evidence syntheses
Applicants should demonstrate knowledge of current research in the field and of systematic review methods and state how these would apply to the question posed. Valid and reliable methods should be proposed for identifying and selecting relevant material, assessing its quality and synthesising the results. Guidance on choice of appropriate methods is contained in NHS CRD Report Systematic Reviews: CRD’s guidance for undertaking reviews in health care (third edition).
Applicants wishing to produce and maintain a Cochrane systematic review from a HTA commissioned systematic review should make the case in their proposal. This will need to include the approval of the relevant Cochrane Review Group. Any additional costs associated with the initial preparation of a Cochrane review should be included in your project proposal. Maintenance costs cannot be met.
It is the policy of NIHR, HTA that all search strategies undertaken as part of evidence synthesis/secondary research projects must not be more than 12 months out of date when the draft final report is submitted. We expect that most projects will manage to bring their searches up to date prior to analysis and writing up. As research funders we are aware that exceptional circumstances can apply that would not allow this to be case but this must be the exception rather than the rule and will be assessed on a case by case basis. The expectation is that projects funded by the HTA Programme will deliver information that is both relevant and timely.
In addition, in order to inform decisions on whether and when to update the review, researchers will be expected to give some indication of how fast the evidence base is changing in the field concerned, based on the nature and volume of on-going work known at the time the review is completed. Applicants should note that they will not be expected to carry out any future updating as part of the contract to complete the review.
Requirements for systematic reviews to be registered with PROSPERO
Applicants undertaking systematic reviews should note the commitment of NIHR to register them in the PROSPERO database. PROSPERO was developed by the NIHR’s Centre for Reviews and Dissemination (CRD), and is the first online facility to register systematic reviews for research about health and social care from all around the world. Access is completely free and open to the public. PROSPERO registration is a condition of NIHR funding for eligible systematic reviews. Link to PROSPERO website.
NIHR carbon reduction guidelines and sustainability
The NIHR is committed to playing a role in helping to meet the UK Net Zero carbon targets. The NIHR would therefore encourage all applications to consider, where feasible, addressing issues of environmental sustainability including their impact and appropriate outcomes within the remit of the applying programme. Advice can be obtained from the NIHR Carbon reduction Guidelines.
In line with the government’s transparency agenda, any contract resulting from this tender may be published in its entirety to the general public. Further information on the transparency agenda is at:
Guidance for using the electronic online Stage 1 application form
To access the application form for Stage 1 applications only
Select the call to which you wish to apply for on the funding opportunity page on the NIHR website. From within the call details page press the ‘Click here to apply’ button to access the Stage 1 application form. This also provides call specific supplementary information e.g. the commissioning brief or specification document. This will direct you to the REALMS login page. If you already have a username (email address) and password, enter these details or, if you have not yet registered, complete the short registration process. You will then be directed to the confirmation page for the specific call. If this is the correct call, click on the Apply button and this will start the application process. Clicking Cancel will return you to your ‘home page’.
Applying for a funding opportunity creates a task called ‘Pending Application’. This task will be available for you to complete until 1pm on the closing date as indicated on the research call and on your task list.
The ‘Pending Application’ task can be accessed at any time until you either submit the application (using the Submit button in the application) or the call closes.
Clicking on the relevant Pending Application link takes you to the online application where you can complete your application information.
Additional guidance will be available on most screens as you progress through your application.
REALMS can be accessed directly, on your home page all your applications and other tasks will be listed.
To submit a Stage 1 application
In order to submit a Stage 1 application to the programme you must:
- Complete all mandatory fields as indicated with a red asterisk *. When you click the 'Info still required' button at the bottom of the online application page a list of outstanding information (hyperlinked to the relevant section/question) will be displayed at the top of the application screen.
- For primary research you should upload a flow diagram (single-side of A4), as a separate .pdf file, for submission with your application form. This should illustrate the study design and the flow of participants (if appropriate). If the project consists of more than one work package, consider a diagram that conveys the sequence and timing of research packages as well as how the work packages are linked. Applicants should also describe complex interventions and controls as accurately and fully as possible within their diagram. If proposing an RCT, we advise you refer to the CONSORT statement and website for guidance. Alternatively, you may find the EQUATOR Network website useful. The .PDF file must be submitted along with your application form.
- Submit a list of references used throughout your proposal using either the Vancouver or Harvard referencing conventions (maximum 1 sides of A4).
- Upload any other requested documents e.g. cover letter, collaborative documents, as dictated by the specification of the call.
Giving others access to the form
Co-applicants: Access to your application is through your user login to REALMS. This should not be shared. The Stage 1 application does not require co-applicants to complete this form however as lead applicant you must ensure they are aware of being involved in the study team. If you want to share your form with your co-applicants, please create a PDF of the form and send it to them. Options to create a PDF are available on the Home page and the Review and Submit page. Where appropriate to the study a Joint Lead applicant can be added to the application (stage 1 and stage 2) and full access can be provided.
Guidance for using the electronic online Stage 2 application form
To access the application form for Stage 2 applications only
If you have been shortlisted from a Stage 1 application:
- The ‘Pending Application’ task can be accessed at any time until you either submit the application (using the Submit button in the application) or the call closes.
- Clicking on the Pending Application link takes you to the application’s main page where you can complete your application information (clicking on this link will not submit an incomplete application).
- Additional guidance will be available on most screens as you progress through your application.
- REALMS can always be accessed directly, on your home page all your applications and other tasks will be listed.
To submit a Stage 2 application
In order to submit a Stage 2 application to the programme you must:
- Complete all mandatory fields. When you click the 'Info still required' button at the bottom of the online application page a list of outstanding information (hyperlinked to the relevant section/question) will be displayed at the top of the application screen.
- Submit a Detailed Research Plan, which should:
- Have a font size of 11 Arial,
- Not exceed 20 A4 pages
- Have a header containing your allocated project reference number if known
- Have a footer showing your page numbers
- Be converted to a .PDF version before uploading it
- Submit a flow diagram (single-side of A4), as a separate .pdf file, for submission with your application form. This should illustrate the study design and the flow of participants (if appropriate). If the project consists of more than one work package, consider a diagram that conveys the sequence and timing of research packages as well as how the work packages are linked. Applicants should also describe complex interventions and controls as accurately and fully as possible within their diagram. If proposing an RCT, we advise you refer to the CONSORT statement and website for guidance. Alternatively, you may find the EQUATOR Network website useful. The .pdf file must be submitted along with your application form.
- Submit a CTU letter of support if appropriate to the study. This is not a mandatory upload.
- Submit a list of references used throughout your proposal (maximum 3 sides of A4).
- Upload any other requested documents e.g. cover letter, collaborative documents as dictated by the specification of the call.
Giving others access to the Stage 2 form
Including Joint lead applicant / co-applicants in your Stage 2 application
Access to your application is through your REALMS user login. This should not be shared. The Stage 2 application is designed as a collaborative submission. As the lead applicant, you can nominate a Joint lead applicant / co-applicants to provide their personal information via the Applicant Detail Form and collaborate on sections of the application. You select the type of access they have to the application. As a result of the nomination, your joint lead applicant / co-applicants will be invited via email to login to REALMS, accept their role and complete their application tasks.
If your application includes Joint lead applicant / co-applicants, you will not be able to complete and submit your application until the co-applicant has provided the information that we require from them.
Once you have completed the details for each co-applicant you should click on the 'Save' button before clicking on the 'Invite' button. This will then prompt an email to be sent to each co-applicant with a task for them to approve involvement with the project in question and provide the necessary personal information via the Applicant Detail Form.
The Stage 2 Application, depending on the access permissions granted by the lead applicant, allows the Joint lead applicant / co-applicant to read and/or amend any details in the application. It is the responsibility of the lead applicant to ensure that the Joint lead applicant / co-applicants complete all the tasks generated. Please make sure that you:
- Enter co-applicants details accurately as we will use these to contact them (the exact email address used as their REALMS username is essential to ensure they receive the automatic communication as part of the application process).
- Allow sufficient time for your Joint lead applicant / co-applicants to complete both parts of their task in the online form before the application deadline.
Completing the form
In line with other health research funders, NIHR have implemented a researcher identification scheme – ORCiD. In order to submit your Stage 1 and Stage 2 application, you (and Joint Lead Applicant/Co-applicants) are required to obtain a free unique ORCiD ID number and enter this onto your REALMS user profile contact information. You will only have to do this once, however if you add any additional information to ORCiD, you will then need to synchronise this with your REALMS account by going to My Profile > ORCiD > Re-import Data. The requirement for an ORCID ID is mandatory for all applicants except PPI co-applicants. However, if a PPI co-applicant has an ORCiD account and wishes to add this to their REALMS contact profile they can.
To do this go to the ‘Profile’ tab on your REALMS Home page and click on the ORCiD link in the left navigation bar to import your profile. On the next screen either add or register for an ORCiD ID by clicking on ‘Create or connect your ORCiD ID’ which will redirect you to the ORCiD website, where you will be able sign in or register for an ID number. Once you have registered and authorised your ID you will be redirected back to your REALMS Contact Information page where your ORCiD ID will now be displayed. More information about ORCiD is available.
Saving your form
As you work through the application, you are asked to 'Save Draft'. This will save all the information you have submitted so far. You can save the form at any point and leave the application prior to submission. The Save Draft button is always located at the bottom of each page of the application. The pending application task will remain on your home page until complete and submitted or the deadline for the application has passed, at which point it will appear as either a Submitted Application or a Past Application task.
It is important to remember to ‘Save Draft’ as you go through the form before navigating away from the page.
There is a security time out set on the REALMS so that after 60 minutes of inactivity, the user will be logged out of the system. It is advisable therefore to save your work at regular intervals using the Save Draft button on any page. REALMS will give you a warning that you are due to be timed out 10 minutes before it times you out. If this message is displayed, you should close the pop-up.
There is a left hand navigation menu in the application so you can select specific parts of the form to complete, however you should always ensure that you save any information entered on your page before using this left hand menu.
Leaving the application task
You can leave your application task at any time. As long as you have saved any new information you have entered for the application, you can navigate to your home page or log out of the REALMS system.
If you encounter any problems with the REALMS system, you should contact the programme funding support team via email.
Space restrictions when entering text
You should be aware that there are character limits set for each text box within the application form. For larger text areas these are indicated with ‘xxx characters left’ at the bottom of the text entry box. Please note that the system does not provide a spell checker. Carriage returns and spaces are counted as characters.
The form counts all blank space as a part of the content of each box, so if you are short of space it will help if you delete extra carriage returns and place any bulleted lists into paragraph format.
You may wish to include URL links to your application or refer to URL links in a body of your text. You are advised not to use any URL shortening service such as ‘tiny.cc’ when completing your application. This type of shortening service is associated with hacking and spamming (as it promotes the sending of links that are unclear where they are pointing).
Review and submit application
Please ensure that before you submit your application, you have completed the required fields and saved a version of your form. You must submit your application form and flow diagram / references where required, by the stated deadline before 1pm. We are unable to grant any time extensions and the deadline will be strictly observed. You should therefore plan your application carefully. We will not enter into negotiations for extensions.
Stage 1 and Stage 2 applications must be submitted electronically.
The HTA Programme no longer requires paper copies of submissions.
Submit your application using the 'Submit' button at the bottom of the form. Clicking on the 'Info still required' button will take you to a list of outstanding/incomplete required application information. Each item listed is an active link that will take you to the relevant application question/field.
We strongly advise applicants at this point to check that all sections are completed and the correct documents have been uploaded into the system as they cannot be altered once submitted.
You will then receive an automated confirmation email from the HTA. If you do not receive an email please contact us immediately as there may be an issue with your submission.
Seven days prior to the closing date you will receive an email reminder that you have an open application (i.e. not submitted). The HTA Programme no longer supports ‘rolling over’ of applications to a subsequent call.
If, after carefully reading all the instructions, you still have difficulties completing your application, please visit the HTA section of the NIHR website which has various supporting documents available.
Any questions, queries or requests for clarification in relation to the call you are applying to should be to one of the following e-mail addresses with the reference number and title for the call for proposals as the email header.
Please be aware that while every effort will be made to respond to enquiries in a timely fashion, it is advisable to send queries in as far in advance of the call closing date as possible to ensure we can respond whilst still leaving you enough time to complete your application.